Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Keywords

Medicine, Breast cancer, Anthracycline, Cyclophosphamide, Chemotherapy

References

No references recorded for this paper.

Cited by

• Issues of Regret in Women With Contralateral Prophylactic MastectomiesAnastasija Sulce — 1999
• Prospects for cancer prevention.Betty Y. Ashbaker, Jill Morgan — 1999
• The effect of less than definitive care on breast carcinoma recurrence and mortalityPaul A. Giguère — 2000
• The role of hormonal therapy in breast cancerMatthew S. Becker — 1998
• Intensive adjuvant chemotherapy for breast cancerRobert Leonard — 1999
• Predictive factor for the response to adjuvant therapy with emphasis in breast cancerJosé Antonio Mujika Casares — 2001
• Adjuvante Chemotherapie beim MammakarzinomVolker Möbus, R. Kreienberg — 2005
• Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutationsRobert Baldock — 2002
• Aromatase Inhibitors in Early Hormone Receptor-Positive Breast CancerSarah Needleman, Jeffrey Tobias — 2008
• Delay in adjuvant radiation treatment and outcomes of breast cancer – a reviewПырчев Сергей Вячеславович — 2002
• Treatment for anthracycline-pretreated metastatic breast cancer.Ramle Muhammad Muslim — 2002
• Advanced age and adjuvant tamoxifen prescription in early‐stage breast carcinoma patientsM. A. McMahan — 2002
• The effect of high dehydroepiandrosterone sulfate levels on tamoxifen blockade and breast cancer progression.圭 渡部, 修 廣田 — 2003
• Does stage at diagnosis influence the observed relationship between socioeconomic status and breast cancer incidence, case-fatality, and mortality?K. Robin Yabroff, Leon Gordis — 2003
• Clinical Testing of Supplementation Therapy in Early Stage Breast Cancer: Pitfalls and OpportunitiesJane Y. Howe, Harry M. Meyer, David J. Burton — 2003
• Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates.Laszlo Gyugyi, R.A. Otto — 2005
• Hormonal therapy for primary breast cancer: Scientific rationale and status of clinical researchS. D. Williams, Matt A. King — 2005
• Long-Term Complications of Adjuvant Chemotherapy for Early Stage Breast CancerAnn H. Partridge, Eric P. Winer — 2004
• Dose-dense adjuvant chemotherapy for primary breast cancerJ. Böing — 2005
• Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.三奈 若林 — 2005

Related papers

• Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patientsZhan Wang, Juan Chen, Meizuo Zhong — 2017
• Expression of topoisomerase IIα in breast cancer neoadjuvant chemotherapy patientsLI Song-q, Songqi Li — 2009
• The Relationship of TOPII Expression and Neoadjuvant Chemotherapy in Breast CancerFeng Jin — 2011
• Changes of Topoisomerase IIα Expression in Breast Tumors after Neoadjuvant Chemotherapy Predicts Relapse-Free SurvivalNicola Tinari, Rossano Lattanzio, Clara Natoli — 2006
• Very low-dose adjuvant chemotherapy in steroid receptor negative stage I breast cancer patients. Austrian Breast Cancer Study Group.R. Jakesz, H. Samonigg, Michael Gnant — 1998
• Adjuvant chemotherapy for breast cancer--30 years later.Mark N. Levine, Timothy J. Whelan — 2006
• Anthracyclines and the tailoring of treatment for early breast cancer.Martine Piccart — 2006
• High expression of TIMP-1 in human breast cancer tissues is a predictive of resistance to paclitaxel-based chemotherapyDongliang Zhu, Xiaoming Zha, Meiling Hu — 2012
• The place of chemotherapy in the treatment of early breast cancer.A. Buzdar — 1998